|Bid||98.00 x 1200|
|Ask||113.47 x 900|
|Day's range||111.94 - 113.99|
|52-week range||56.91 - 115.73|
|Beta (3Y monthly)||0.51|
|PE ratio (TTM)||112.60|
|Earnings date||20 Jan 2020 - 24 Jan 2020|
|Forward dividend & yield||0.80 (0.71%)|
|1y target est||118.83|
PRA Health (PRAH) is gaining steadily from expansion in international markets, solid 2019 outlook and growing CRO industry. However, escalating direct costs remain a woe.
Cooper Companies' (COO) CVI Unit has receives FDA approval for its MiSight 1 day contact lens, which complements its commitment to eye health innovation.
Cooper Companies (COO) is gaining traction from expansion in international markets, robust product portfolio across segments and prudent acquisitions. However, forex continues to remain a concern.
Dentsply (XRAY) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
Conmed (CNMD) has been upgraded to a Zacks Rank 2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
CONMED's (CNMD) Q3 earnings gain from higher revenues, solid segmental performance and margin expansion. However, high long-term debt remains a concern.
Conmed (CNMD) delivered earnings and revenue surprises of 10.71% and 2.32%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?
Conmed (CNMD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
When you buy a stock there is always a possibility that it could drop 100%. But on the bright side, you can make far...
HMS Holdings (HMSY) is gaining traction from growing PI and TPM analytical services as well as robust margins despite intense competition.
The collaboration with GetWellNetwork is likely to allow Cerner (CERN) in enhancing functionality for clients and patients through third-party solutions.
Strong international footprint, solid prospects in the global orthopedic space and an enhanced product pipeline bode well for Wright Medical (WMGI). However, adverse forex mars prospects.
Nevro (NVRO) is gaining traction from a fortified international footprint and solid prospects in the SCS market. However, stiff competition remains a woe.